ổn định và 4 mắt thị lực giảm. Tỉ lệ mắt tăng thị lực ở giai đoạn sớm và bệnh nhân trên 10 tuổi cao hơn có ý nghĩa thống kê so với mắt giai đoạn muộn và bệnh nhân dưới 10 tuổi. Kết luận: Kết quả điều trị ban đầu bệnh Coats tại bệnh viện Mắt Trung ương đạ

Phú Nguyễn Minh, Trung Hầu Dương, Hằng Trần Thị, Huy Nguyễn Văn, Tịnh Nguyễn Xuân, Hà Nguyễn Ngân, Giang Nguyễn Hạnh, Dương Nguyễn Thị Nga

Main Article Content

Abstract

Objects: To evaluate the initial treatment outcomes of Coats disease at the Vietnam National Eye Hospital. Subjects and Methods: This is a retrospective case series from a single center of children diagnosed with Coat’s disese at Vietnam National Eye Hospital. Patients were followed up for at least 6 months post-treatment. Treatment outcomes were assessed based on retinal condition and visual acuity after treatment. Results: From September 2022 to September 2024, a total of 31 eyes from 30 patients (29 males and 1 female) were diagnosed with Coats disease. The mean age of the patients was 8.53 ± 5.36 years. Stage 2B was the most common, with 10 eyes, while Stage 2A was the least common, with 1 eye. The primary treatment modality was photocoagulation for early stages and cryotherapy for advanced stages. Intravitreal anti-VEGF injections were used as adjunctive therapy in 17 eyes. The mean follow-up duration was 17 months. After treatment, 28 eyes (90.3%) achieved retinal reattachment. However, 7 eyes still exhibited vitreoretinal proliferation. Visual acuity (Snellen) improved in 11 eyes, remained stable in 16 eyes, and decreased in 4 eyes. Eyes treated at earlier stages and patients over 10 years old showed a statistically significant higher rate of visual acuity improvement compared to eyes at later stages and patients under 10 years old. Conclusion: Initial treatment outcomes for Coats disease at the Vietnam National Eye Hospital demonstrated anatomical success, preserving the globe for patients. Visual acuity improvement was observed in patients treated at earlier stages.

Article Details

References

1. Shields CL, Udyaver S, Dalvin LA, et al. Coats disease in 351 eyes:Analysis of features and outcomes over 45 years (by decade) at a single center.Indian J Ophthalmol.2019;67(6).
2. Kang HG, Kim JD, Choi EY, et al. Clinical features and prognostic factors in 71 eyes over 20 years from patients with Coats’ disease in Korea.Sci Rep.2021;11(1):6124.
3. Li AS, Capone A, Trese MT, et al. Long-Term Outcomes of Total Exudative Retinal Detachments in Stage 3B Coats Disease. Ophthalmology. 2018;125(6): 887-893.
4. He YG, Wang H, Zhao B,Lee J, Bahl D, McCluskey J. Elevated vascular endothelial growth factor level in Coats’ disease and possible therapeutic role of bevacizumab.Graefes Arch Clin Exp Ophthalmol Albrecht Von Graefes Arch Klin Exp Ophthalmol.2010;248(10):1519-1521.
5. Oli A, Balakrishnan D, Jalali S. Coats’ disease: trends and long-term treatment outcomes in a tertiary referral centre.Ther Adv Ophthalmol. 2021;13:25158414211055957.
6. Ramasubramanian A, Shields CL. Bevacizumab for Coats’ disease with exudative retinal detachment and risk of vitreoretinal traction.Br J Ophthalmol.2012;96(3):356-359.
7. Mulvihill A, Morris B.A. Population-based study of Coats disease in the United Kingdom II: investigation, treatment, and outcomes.Eye. 2010;24(12):1802-1807.
8. Al-Qahtani AA, Almasaud JM, Ghazi NG. Clinical characteristics and treatment outcomes of coats disease in a saudi arabian population. Retina.2015;35(10):2091-2099.